

*Not for distribution or release in the United States or to U.S. persons*

ASX Announcement

4th July 2024

## **GENETIC SIGNATURES COMPLETES UNDERWRITTEN RETAIL ENTITLEMENT OFFER**

Genetic Signatures Limited ACN 095 913 205 (ASX: GSS) (Genetic Signatures) is pleased to announce the completion of the retail component of its fully underwritten Entitlement Offer (details of which were announced to the market on 4 June 2024) (Retail Entitlement Offer) which raised approximately \$8.5 million.

The Retail Entitlement Offer took place in conjunction with a placement to institutional investors (Placement) and a fully underwritten 1 for 5.82 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares (New Shares) to raise approximately \$30 million. The Placement and institutional component of the Entitlement Offer were successfully completed in June 2024, raising approximately \$21.5 million.

The Retail Entitlement Offer provided eligible retail shareholders in the Company (Eligible Retail Shareholders) the opportunity to subscribe for 1 New Share for every 5.82 existing fully paid ordinary shares which they held as at 7.00pm (Sydney, Australia time) on Thursday, 6 June 2024 at a price of \$0.75 per New Share.

The Retail Entitlement Offer closed at 5.00pm (Sydney, Australia time) on Monday, 1 July 2024 with valid applications for entitlements received raising approximately \$0.7 million. The shortfall after the issue of New Shares from the Retail Entitlement Offer, being approximately \$7.8 million, will be allocated to the underwriters of the Retail Entitlement Offer. The shortfall is comprised of entitlements not taken up by Eligible Shareholders.

The settlement date for New Shares to be issued under the Retail Entitlement Offer is Friday, 5 July 2024 and the issue of New Shares under the Retail Entitlement Offer is scheduled to occur on Monday, 8 July 2024, with those shares expecting to commence trading on the ASX on Tuesday, 9 July 2024. New Shares issued under the Retail Entitlement Offer will rank equally in all respects with existing ordinary shares on issue with effect from their date of issue.

Bell Potter Securities Limited and Taylor Collison Limited acted as joint lead managers to the Offer and as underwriters to the Entitlement Offer.

Eligible Shareholders should confirm the actual number of New Shares issued to them before trading in such shares, and the sale by any Eligible Shareholder of New Shares prior to receiving their holding statement is at their own risk.

The Board of Genetic Signatures wishes to thank all Eligible Retail Shareholders who participated in the Retail Entitlement Offer.

– ENDS –

## Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr Neil Gunn**  
Director and  
Interim Chief Executive Officer  
[neil.gunn@geneticsignatures.com](mailto:neil.gunn@geneticsignatures.com)  
T: +61 (0)2 9870 7580

**Karl Pechmann**  
Chief Financial and Operating Officer  
and Company Secretary  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.